Research Priorities - Cancer
  • Article
  • May 16 2023

Markey Research Day is an opportunity for researchers who study any aspect of cancer to share their work and receive feedback from colleagues across campus.

  • Article
  • May 4 2023

The University of Kentucky Markey Cancer Center has been recognized by the National Pancreas Foundation (NPF) as an approved NPF Center of Excellence.

  • Article
  • Apr 19 2023

Markey Cancer Center researchers identified a protein that plays an important role in prostate cancer progression as well as resistance to enzalutamide, a common prostate cancer treatment.

  • Article
  • Apr 17 2023

A recent University of Kentucky Markey Cancer Center study reveals that having depression before or after a breast cancer diagnosis was associated with a lower likelihood of survival.

  • Article
  • Apr 14 2023

The University of Kentucky Markey Cancer Center’s Biospecimen and Translational Pathology Shared Resource Facility (BPTP SRF) was awarded accreditation from the College of American Pathologists (CAP) based on results of a recent on-site inspection.

  • Article
  • Mar 28 2023

A new University of Kentucky Markey Cancer Center study published in JCO Oncology Practice found that the use of a financial navigator can significantly reduce financial toxicity for patients with hematologic cancer and their caregivers.

  • Article
  • Mar 16 2023

Since 2002, colorectal cancer screenings have doubled in Kentucky, which has led to a more than 30% decrease in incidence and mortality rates.

  • Article
  • Mar 15 2023

Sally Ellingson, Ph.D. is an assistant professor at the Institute for Biomedical Informatics and also works with the Cancer Research Informatics Shared Resource Facility at the Markey Cancer Center.

  • Article
  • Mar 10 2023

The College of Pharmacy  will host its 11th annual Therapeutics, Outcomes, Discovery & Delivery (TODD) Symposium from 8 a.m.–5 p.m. April 12, at the Lee T. Todd, Jr. Building.

  • Article
  • Feb 24 2023

A recent University of Kentucky Markey Cancer Center study suggests a new radiopharmaceutical compound may be a viable treatment option for patients with advanced cervical cancer.